Phosphorus binder composition for treatment of hyperphosphatemia
AssigneeBioLink Life Sciences, Inc.
InventorDeanna J. Nelson
Life of this patent
Estimating the term…
Abstract
The present invention relates to oral pharmaceutical products which are useful for binding phosphorus in ingesta, and inhibiting absorption of phosphorus from the gastrointestinal tract of subjects. A method for binding phosphorus in ingesta and inhibiting its absorption from the gastrointestinal tract is also provided. The pharmaceutical products and methods of the present invention are particularly useful in the treatment of hyperphosphatemia of chronic uremia and reducing serum phosphorus levels in patients requiring such therapy.
Claims19
A method of inhibiting absorption of phosphorus-containing anions from the gastrointestinal tract of a subject comprising orally administering to the subject a phosphorus-containing anion-binding composition in a quantity sufficient to bind with said phosphorus-containing anions in the gastrointestinal tract of the subject, wherein said phosphorus-containing anion-binding composition comprises a calcium succinate composition.
A method of inhibiting absorption of phosphorus from the gastrointestinal tract of a subject comprising orally administering to the subject a phosphorus-containing anion-binding composition in a quantity sufficient to bind with phosphorus-containing anions in the gastrointestinal tract, wherein said phosphorus-containing anion-binding composition comprises a calcium succinate composition and the phosphorus-containing anion-binding composition is administered at a time close time to the time of consumption of food or beverages by the subject.
A pharmaceutical composition useful for treating hyperphosphatemia in a warm-blooded animal comprising a phosphorus-containing anion-binding composition comprising a quantity of a calcium succinate composition sufficient to bind with phosphorus-containing anions in the gastrointestinal tract of the subject.
A method for reducing the serum phosphorus level in the blood of a subject comprising orally ingesting a phosphorus-containing anion-binding composition comprising a quantity of a calcium succinate composition sufficient to bind with phosphorus-containing anions in the gastrointestinal tract of the subject, thereby inhibiting phosphorus uptake into the systemic circulation of the subject.
A method of inhibiting absorption of phosphorus from the gastrointestinal tract of a subject and reducing the risk of side effects comprising orally administering to the subject at a time close time to the time of consumption of food or beverages by the subject a phosphorus-containing anion-binding composition comprising first quantity of a phosphorus-containing anion-binding composition of a calcium succinate composition sufficient to bind with phosphorus-containing anions in the gastrointestinal tract and a second quantity of a stool softener selected from the group consisting of poly(ethylene glycol) having a molecular weight between about 1,500 Daltons and about 10,000 Daltons, lactulose, lactitol, magnesium ascorbate, magnesium citrate, alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, and a pharmaceutically acceptable beta-cyclodextrin derivative.
Dependencies are inferred from the claim text.